Strategy & Planning
A BioVertex strategy engagement starts with the decision the company actually has to make: what to develop, for whom, by when, and with what capital. We do not deliver a generic corporate-strategy deck. We build the Target Product Profile, the integrated development roadmap, and the competitive story that your board and investors will pressure-test.
That work sits upstream of program management. If the TPP is vague, CMC, nonclinical, and clinical workstreams will fight each other. If the roadmap ignores CDMO lead times or regulatory sequencing, the Gantt chart is fiction. We have built these plans inside Novartis, Biogen, Editas Medicine, Tessera Therapeutics, and now as an embedded partner for early-stage teams.
Typical outputs: a decision-ready TPP, a stage-gated development roadmap with resource implications, a competitive intelligence brief, and BD or investor materials that match the science rather than oversell it.
What you get
- Target Product Profile (indication, patient, product, claims, and development implications)
- Integrated development roadmap from discovery or candidate selection through the next value-inflection milestone
- Resource and budget framing aligned to the plan, not to a fundraising round's optics
- Competitive intelligence and positioning for investors, partners, and KOLs
- Business development and market-outreach narrative when the science is ready to leave the lab
Who this is for
Academic teams moving toward a first institutional round, Pre-Seed to Series B biotechs that need a real development thesis, and VC firms that want an independent read on a target's plan.
Related reading: Turning Science into Actionable Strategy. VC diligence and portfolio buildout live on For VC Firms.